UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Billings L
(2022)
Statistical evidence for high-penetrance MODY-causing genes in a large population-based cohort
in Endocrinology, Diabetes & Metabolism
Binks S
(2022)
036 A GWAS of LGI1-antibody encephalitis
in Journal of Neurology, Neurosurgery & Psychiatry
Bisharat L
(2020)
Hot melt extruded zein for controlled delivery of diclofenac sodium: Effect of drug loading and medium composition.
in International journal of pharmaceutics
Blair DR
(2022)
Common genetic variation associated with Mendelian disease severity revealed through cryptic phenotype analysis.
in Nature communications
Bland VL
(2023)
Metabolically favorable adiposity and bone mineral density: a Mendelian randomization analysis.
in Obesity (Silver Spring, Md.)
Bland VL
(2022)
Cross-sectional associations between adipose tissue depots and areal bone mineral density in the UK Biobank imaging study.
in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
Blass I
(2022)
Revisiting the Risk Factors for Endometriosis: A Machine Learning Approach.
in Journal of personalized medicine
Blauw LL
(2021)
Common Genetic Variation in MC4R Does Not Affect Atherosclerotic Plaque Phenotypes and Cardiovascular Disease Outcomes.
in Journal of clinical medicine
Blauwendraat C
(2021)
A population scale analysis of rare SNCA variation in the UK Biobank.
in Neurobiology of disease
Boguslavskyi A
(2021)
Phospholemman Phosphorylation Regulates Vascular Tone, Blood Pressure, and Hypertension in Mice and Humans.
in Circulation
Bonfiglio F
(2018)
Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome.
in Gastroenterology
Bonfiglio F
(2021)
GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome
in Cell Genomics
Boonpor J
(2022)
Combined association of walking pace and grip strength with incident type 2 diabetes.
in Scandinavian journal of medicine & science in sports
Boonpor J
(2022)
Types of diet, obesity, and incident type 2 diabetes: Findings from the UK Biobank prospective cohort study.
in Diabetes, obesity & metabolism
Boonpor J
(2021)
Associations between grip strength and incident type 2 diabetes: findings from the UK Biobank prospective cohort study.
in BMJ open diabetes research & care
Border R
(2019)
Imputation of behavioral candidate gene repeat variants in 486,551 publicly-available UK Biobank individuals.
in European journal of human genetics : EJHG
Border R
(2022)
Assortative mating biases marker-based heritability estimators.
in Nature communications
Border R
(2022)
Cross-trait assortative mating is widespread and inflates genetic correlation estimates.
in Science (New York, N.Y.)
Borga M
(2023)
Advanced Body Composition Assessment: From Body Mass Index to Body Composition Profiling
in Journal of Investigative Medicine
Borga M
(2022)
Basic Protocols in Foods and Nutrition
Borges MC
(2022)
The impact of fatty acids biosynthesis on the risk of cardiovascular diseases in Europeans and East Asians: a Mendelian randomization study.
in Human molecular genetics
Bortsov AV
(2022)
Brain-specific genes contribute to chronic but not to acute back pain.
in Pain reports
Borziak K
(2022)
X-linked genetic risk factors that promote autoimmunity and dampen remyelination are associated with multiple sclerosis susceptibility
in Multiple Sclerosis and Related Disorders
Bos MM
(2021)
Genetically Determined Higher TSH Is Associated With a Lower Risk of Diabetes Mellitus in Individuals With Low BMI.
in The Journal of clinical endocrinology and metabolism
Boschesi Barros V
(2022)
Mortality, survival, and causes of death in mental disorders: comprehensive prospective analyses of the UK Biobank cohort
in Psychological Medicine
Boulund U
(2022)
Gut microbiome associations with host genotype vary across ethnicities and potentially influence cardiometabolic traits.
in Cell host & microbe
Bountziouka V
(2023)
Dietary Patterns and Practices and Leucocyte Telomere Length: Findings from the UK Biobank.
in Journal of the Academy of Nutrition and Dietetics
Bountziouka V
(2022)
Modifiable traits, healthy behaviours, and leukocyte telomere length: a population-based study in UK Biobank.
in The lancet. Healthy longevity
Bountziouka V
(2021)
Impact of Persisting Amblyopia on Socioeconomic, Health, and Well-Being Outcomes in Adult Life: Findings From the UK Biobank.
in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Bountziouka V
(2022)
Association of shorter leucocyte telomere length with risk of frailty.
in Journal of cachexia, sarcopenia and muscle
Bourfiss M
(2022)
Prevalence and Disease Expression of Pathogenic and Likely Pathogenic Variants Associated With Inherited Cardiomyopathies in the General Population.
in Circulation. Genomic and precision medicine
Bourgeron T
(2022)
Chapeau UK Biobank! A revolution for integrated research on humans and large-scale data sharing.
in Comptes rendus biologies
Boutin TS
(2020)
Insights into the genetic basis of retinal detachment.
in Human molecular genetics
Bovijn J
(2019)
GWAS Identifies Risk Locus for Erectile Dysfunction and Implicates Hypothalamic Neurobiology and Diabetes in Etiology.
in American journal of human genetics
Bowden J
(2021)
The Triangulation WIthin a STudy (TWIST) framework for causal inference within pharmacogenetic research.
in PLoS genetics
Bowden SJ
(2021)
Genetic variation in cervical preinvasive and invasive disease: a genome-wide association study.
in The Lancet. Oncology
Bowman K
(2019)
Vitamin D levels and risk of delirium: A mendelian randomization study in the UK Biobank.
in Neurology
Bowring A
(2021)
Confidence Sets for Cohen's d effect size images.
in NeuroImage
Bracher-Smith M
(2022)
Machine learning for prediction of schizophrenia using genetic and demographic factors in the UK biobank.
in Schizophrenia research
Bracher-Smith M
(2022)
Whole genome analysis in APOE4 homozygotes identifies the DAB1-RELN pathway in Alzheimer's disease pathogenesis.
in Neurobiology of aging
Bragg F
(2022)
Predictive value of circulating NMR metabolic biomarkers for type 2 diabetes risk in the UK Biobank study
in BMC Medicine
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |